463 related articles for article (PubMed ID: 22337679)
1. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.
Thadhani R; Appelbaum E; Pritchett Y; Chang Y; Wenger J; Tamez H; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata J; Thompson BT; Andress D; Zhang W; Packham D; Singh B; Zehnder D; Shah A; Pachika A; Manning WJ; Solomon SD
JAMA; 2012 Feb; 307(7):674-84. PubMed ID: 22337679
[TBL] [Abstract][Full Text] [Related]
2. Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.
Wang AY; Fang F; Chan J; Wen YY; Qing S; Chan IH; Lo G; Lai KN; Lo WK; Lam CW; Yu CM
J Am Soc Nephrol; 2014 Jan; 25(1):175-86. PubMed ID: 24052631
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease.
Tamez H; Zoccali C; Packham D; Wenger J; Bhan I; Appelbaum E; Pritchett Y; Chang Y; Agarwal R; Wanner C; Lloyd-Jones D; Cannata J; Thompson BT; Andress D; Zhang W; Singh B; Zehnder D; Pachika A; Manning WJ; Shah A; Solomon SD; Thadhani R
Am Heart J; 2012 Dec; 164(6):902-9.e2. PubMed ID: 23194491
[TBL] [Abstract][Full Text] [Related]
4. Questioning the validity of a recent randomized trial on paricalcitol in patients with echocardiographic evidence of cardiac hypertrophy.
Fedele F; Frati G; Biondi-Zoccai G
Int J Cardiol; 2013 Sep; 167(5):2343-4. PubMed ID: 23176772
[No Abstract] [Full Text] [Related]
5. Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease.
Thadhani R; Appelbaum E; Chang Y; Pritchett Y; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata J; Thompson T; Audhya P; Andress D; Zhang W; Ye J; Packham D; Singh B; Zehnder D; Manning WJ; Pachika A; Solomon SD
Am J Nephrol; 2011; 33(2):139-49. PubMed ID: 21242674
[TBL] [Abstract][Full Text] [Related]
6. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
[TBL] [Abstract][Full Text] [Related]
7. The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.
Pritchett Y; Jemiai Y; Chang Y; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata-Andía JB; Thompson T; Appelbaum E; Audhya P; Andress D; Zhang W; Solomon S; Manning WJ; Thadhani R
Clin Trials; 2011 Apr; 8(2):165-74. PubMed ID: 21478328
[TBL] [Abstract][Full Text] [Related]
8. Paricalcitol and endothelial function in chronic kidney disease trial.
Zoccali C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Politi R; Tripepi G; Ghiadoni L; Thadhani R; Mallamaci F
Hypertension; 2014 Nov; 64(5):1005-11. PubMed ID: 25259743
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D therapy and cardiac function in chronic kidney disease.
Slatopolsky E
JAMA; 2012 Jun; 307(21):2254; author reply 2254-5. PubMed ID: 22706822
[No Abstract] [Full Text] [Related]
10. Vitamin D therapy and cardiac function in chronic kidney disease.
Rajagopalan S; Chan CT
JAMA; 2012 Jun; 307(21):2253; author reply 2254. PubMed ID: 22706820
[No Abstract] [Full Text] [Related]
11. Vitamin D therapy and cardiac function in chronic kidney disease.
Fourtounas C
JAMA; 2012 Jun; 307(21):2253; author reply 2254. PubMed ID: 22706819
[No Abstract] [Full Text] [Related]
12. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.
Susantitaphong P; Nakwan S; Peerapornratana S; Tiranathanagul K; Katavetin P; Srisawat N; Praditpornsilpa K; Eiam-Ong S
BMC Nephrol; 2017 Jan; 18(1):19. PubMed ID: 28088187
[TBL] [Abstract][Full Text] [Related]
13. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients.
Sezer S; Tutal E; Bal Z; Uyar ME; Bal U; Cakir U; Acar NO; Haberal M
Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898
[TBL] [Abstract][Full Text] [Related]
14. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Matias PJ; Jorge C; Ferreira C; Borges M; Aires I; Amaral T; Gil C; Cortez J; Ferreira A
Clin J Am Soc Nephrol; 2010 May; 5(5):905-11. PubMed ID: 20203163
[TBL] [Abstract][Full Text] [Related]
15. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D in chronic kidney disease: more questions than answers.
Anker SD; von Haehling S
JAMA; 2012 Feb; 307(7):722-3. PubMed ID: 22337683
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
Cheng J; Zhang W; Zhang X; Li X; Chen J
Clin J Am Soc Nephrol; 2012 Mar; 7(3):391-400. PubMed ID: 22223607
[TBL] [Abstract][Full Text] [Related]
18. Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease.
Cheng S; Coyne D
Expert Opin Pharmacother; 2006 Apr; 7(5):617-21. PubMed ID: 16553577
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.
Hervás Sánchez JG; Prados Garrido MD; Polo Moyano A; Cerezo Morales S
Nefrologia; 2011; 31(6):697-706. PubMed ID: 22130286
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.
Moe SM; Saifullah A; LaClair RE; Usman SA; Yu Z
Clin J Am Soc Nephrol; 2010 Feb; 5(2):299-306. PubMed ID: 20056760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
